University of Louisville homepage
All experts
All experts

Mr.

Goetz Kloecker

Professor

School of Medicine

Orcid identifier0000-0003-4726-3062
  • Professor
    School of Medicine

SPONSORED PROJECTS

Clnical Trials

SPONSORED PROJECTS

  • Showing page 1 out of 3
Showing page 1, sponsored projects 1 to 25 of 51
GRANT
AWD-00000223 | TAK-079-3002: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
PPD Clinical Research_PCR1 Jan 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
SAX101 (SANTANA-225)
1 Jan 2025
MORELEARN MORE
GRANT
231056|BMN 270 - A Long-Term Follow-Up Study in Subjects with Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial
BioMarin Pharmaceutical Inc_BMPI3 Jul 2024
MORELEARN MORE
GRANT
240378|MK-2870 - A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS
Merck and Company Inc_MERCKCO3 Jul 2024
MORELEARN MORE
GRANT
240247|A R, D-B, Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Bristol Myers Squibb_BMS11 Apr 2024
MORELEARN MORE
GRANT
240817|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects with Limited-Stage Small-Cell Lung Cancer who have Not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)
IQVIA RDS Inc_IQVIA11 Jan 2024 - 31 Dec 2029
MORELEARN MORE
GRANT
240591|849-007 - A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Pharmaceutical Resrch Associates Inc_PRA1 Jan 2024
MORELEARN MORE
GRANT
241087|SWOG-S2302: Pragmatica-Lung: Prospective Randomized St of Ramucirumab (LY3009806 NSC 749128) + Pembrolizumab (MK-3475 NSC 776864) v Standard of Care for Participants Previously Treated w Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Oregon Health and Science Universit_OHSU1 Jan 2024
MORELEARN MORE
GRANT
230766|DELFI-L201 - Cancer Screening Assay using DELFI; A Clinical Validation Study in Lung Protocol: DELFI-201
PPD Clinical Research_PCR5 Jan 2023
MORELEARN MORE
GRANT
230892|FF10832-PEM-201 -A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumor
TD2 Precision Oncology_TD2PO2 Jan 2023
MORELEARN MORE
GRANT
230148|PACIFIC-8 D9075C00001 A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose
IQVIA RDS Inc_IQVIA1 Jan 2023
MORELEARN MORE
GRANT
230359|VCN-01 - A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Orion Sante Sarl_OSS1 Jan 2023
MORELEARN MORE
GRANT
230369|ARC-20: A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors
ICON Clinical Research_ICON1 Jan 2023
MORELEARN MORE
GRANT
230750|JNJ-17000139BLC2002 - A Phase 2, OL, MC, R St of TAR-200 in Comb W Cetrelimab & Cetrelimab Alone in Participants W Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy...
PRA Health Sciences Inc_PRA1 Jan 2023
MORELEARN MORE
GRANT
240161|V940-002 - A Phase 3, R, DB, PlC Clinical Study of Adjuvant V940 mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Merck and Company Inc_MERCKCO1 Jan 2023 - 31 Dec 2035
MORELEARN MORE
GRANT
240166|GTM-102 - A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS)
GT Medical Technologies Inc_GTMED1 Jan 2023
MORELEARN MORE
GRANT
230347|FT536-101 -A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors
Fate Therapeutics Inc_FTI9 Jan 2022
MORELEARN MORE
GRANT
230386|DF9001-001 A Ph 1/2, First-In-Human, Multi-Part, OL St to Investigate the Sfty, Tol, Pharmacokinetics, Biological & Clinical Activity of DF9001 as a monotherapy & in comb w nivolumab in Pts w Adv (Unresectable, Recurrent, or Metastatic) Solid Tumors
IQVIA RDS Inc_IQVIA1 Jan 2022
MORELEARN MORE
GRANT
190688|Center for Cancer Immunology and Immunotherapy (CCII)
National Institutes of Health_NIH2 Jan 2020
MORELEARN MORE
GRANT
180493|CA209816 Randomized, Open-label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Bristol Myers Squibb_BMS2 Apr 2019
MORELEARN MORE
GRANT
191028|P719-SUR-Z11 - A Phase 2, Open-Label, MultiCenter, Dose Escalation Study of a Immunotherapeutic Treatment, DPX-Survivac in Combination with Low Dose Cyclophosphamide and Anti-PD-1, in Subjects with Selected Advanced or Recurrent Solid Tumors
Precision Oncology LLC_POL1 Jan 2019
MORELEARN MORE
GRANT
200117|RAPT FLX475 Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Novotech_NOVOTECH1 Jan 2019
MORELEARN MORE
GRANT
180977|LUNAR EF-24 LUNAR: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure Protocol: EF-24
Novocure Inc_NOVOCURE9 Dec 2018
MORELEARN MORE
GRANT
181183|NRG-LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
NRG Oncology Foundation Inc_NRGOF3 Jan 2018
MORELEARN MORE
GRANT
180335|IOV-LUN-201 A Ph 2 Study to Assess the Efficacy & Safety of Autologous Tumor Infiltrating Lympocytes (LN-145) Alone & In Combination w/ Anti-PD-L1 Inhibitor Durvalumab (MED14736) in Patients w/ Locally Adv or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Iovance Biotherapeutics Inc_IBI1 Jan 2018
MORELEARN MORE